摘要
近几十年来,我国的炎症性肠病(IBD)发病率呈上升趋势。目前欧美国家IBD的诊断和治疗已经相当规范,而在我国,鉴别诊断及规范治疗方面均需进行进一步的探讨。
In recent decades, China's inflammatory bowel disease (IBD) incidence has shown an upward trend. Currently, the diagnosis and treatment of IBD in Europe and the United States and other developed countries are quite standardized, while in China, the differential diagnosis and standard treatment need to be further explored. Selection of traditional medicine, biologics research and application, and exploration in stem cell therapy may play roles in exploration of standardized treatment of IBD.
出处
《中国处方药》
2010年第2期34-34,72+5,共1页
Journal of China Prescription Drug